SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is seeing significant investor interest driven by a pivot toward the AI data center power market, with participants pointing to its modular power block technology and active proposal pipeline as key catalysts. The community is actively discussing the stock's potential for institutional accumulation and a possible short squeeze, drawing comparisons to sector peers that have recently seen substantial valuation growth.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is capturing significant community interest and trending status as investors look ahead to its earnings release and recent product launch of a new quantum RF sensing architecture. While some shareholders express frustration with recent price volatility, others are aggressively accumulating shares, citing the company's strong government and defense contract pipeline as a major long-term catalyst.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as investors weigh multi-year lows and a complex turnaround strategy against persistent concerns regarding market share erosion, China-based tariffs, and weak consumer demand. The community is sharply divided, with bulls pointing to deep-value levels and insider buying as a sign of a bottom, while bears remain focused on poor technical momentum and competitive pressure from emerging athletic brands.

Robo.ai, Inc. engages in the design and development of smart electric vehicles. It aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology. The company was founded in 2016 and is headquartered in Dubai, United Arab Emirates.

Robo.ai Inc. - Ordinary Shares - Class B

Robo.ai Inc.

Robo.ai Inc. is capturing significant community attention as traders discuss its potential for a short squeeze, fueled by high borrow fees and ongoing excitement surrounding the debut of its Neurovia AI subsidiary's technology. While the stock has seen volatile price action, the community remains actively focused on holding their positions, interpreting consolidation and pullbacks as accumulation opportunities for a potential move toward higher price levels.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors focus on the company's strategic role as a primary domestic source for rare earth elements, bolstered by government backing and long-term supply agreements. The community is actively debating the stock's sensitivity to U.S.-China trade dynamics while monitoring institutional accumulation and potential short-term volatility ahead of earnings.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as traders closely monitor a potential 18-day strike at Samsung and its implications for global memory supply, while weighing that against recent semiconductor sector profit-taking following a high-profile U.S.-China trade delegation. The community is actively debating whether current pullbacks represent a structural shift in AI-driven demand or a broader market rotation, with many investors viewing the dip as an accumulation opportunity ahead of upcoming tech conferences and major industry earnings.

Energy Vault Holdings, Inc. engages in the provision of energy storage solutions. The company was founded in September 2020 and is headquartered in Westlake Village, CA.

Energy Vault Holdings Inc

Energy Vault Holdings is seeing increased retail interest and active community discussion surrounding its potential to capitalize on the AI data center energy infrastructure boom through its proprietary gravity storage technology. Investors are closely monitoring its strategic partnerships and upcoming earnings reports, as community members speculate on a potential parabolic breakout while navigating ongoing volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending amid intense community polarization over the company's financial health, trading activity, and political fallout from ongoing geopolitical tensions in the Middle East. Discussion is heavily driven by retail sentiment questioning the sustainability of the business model and the company's performance as a broader market indicator.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is experiencing intense volume and volatility as retail and institutional investors rotate into space-related infrastructure stocks ahead of potential SpaceX-related catalysts. While some community members are highlighting institutional accumulation and record contract backlogs as long-term bullish indicators, others are wary of the rapid price swings and potential for dilution, fueling an active debate between those holding for a long-term squeeze and those wary of recurring market manipulation.

T1 Energy, Inc. engages in developing battery solutions. It focuses on energy storage systems and commercial mobility. The company was founded by Tom Einar Jensen, Peter Matrai, and Tore Ivar Slettemoen on August 31, 2023 and is headquartered in Austin, TX.

T1 Energy Inc.

T1 Energy is seeing significant market activity driven by strong Q1 results that beat earnings expectations, paired with a major 10 million share stake disclosure from Situational Awareness. Community discussions are heavily centered on the stock's potential for a short squeeze due to elevated short interest, while investors weigh the impact of new institutional backing against volatility and the company's long-term infrastructure role in the AI data center space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Clene said earlier on Thursday that it plans to submit a New Drug Application for its lead ALS candidate CNM-Au8 in the third quarter of 2026 under the FDA’s accelerated approval pathway.</li><li>Roth Capital analyst dismissed the chances of the drug getting approval on a surrogate endpoint.&nbsp;</li><li>The analyst, however, reiterated a ‘Buy’ rating on the stock and a $30 price target.</li></ul> Shares of Clene Inc. (CLNN) fell 3% after hours on Thursday after a Roth Capital analyst dismissed the chances of the U.S. Food and Drug Administration approving its application for the investigational therapy CNM-Au8 in the treatment of amyotrophic lateral sclerosis on an accelerated basis as a “long shot.”Shares of the company rose 8% during regular trading hours but fell after hours following the analyst note.<h2 class="st-heading-2">Clene’s Plans For Its Investigational Therapy</h2>Clene said earlier on Thursday that it plans to submit a New Drug Application for its lead ALS candidate CNM-Au8 in the third quarter of 2026 under the FDA’s accelerated approval pathway. The FDA's Accelerated Approval pathway allows earlier approval of drugs treating serious or life-threatening conditions with unmet medical needs based on surrogate endpoints reasonably likely to predict clinical benefit, with mandatory confirmatory trials required post-approval to verify benefit.The company’s submission will rely on data showing statistically significant reductions in neurofilament light chain — a key biomarker of neuronal damage — following a constructive meeting with the FDA in the first quarter. Regulators signaled that the NfL results, along with correlations to improved survival and clinical outcomes, may support accelerated approval for ALS, the company said.“We were encouraged by the constructive dialogue during our recent Type C meeting with the FDA,” said Clene CEO Rob Etherington. “People living with ALS continue to need additional treatment options, and we believe CNM-Au8 has the potential to restore and protect neuronal health and function, leading to improved survival.” The company also said on Thursday that it intends to launch a confirmatory late-stage trial in Q1 2027, with overall survival as the primary endpoint.<h2 class="st-heading-2">Analyst Weighs In On Plans</h2>Roth Capital analyst Jonathan Aschoff said that the FDA's agreement to receive Clene's accelerated approval NDA for CNM-Au8 in treating ALS is a positive development, but the firm does not believe that the magnitude of change in neurofilament light will drive approval.The firm added that despite the dire ALS medical need, the much smaller NfL reduction with CNM-Au8 versus Biogen’s Qalsody stokes its pessimism. Qalsody is a prescription, FDA-approved medication specifically for adults with ALS, a progressive, fatal neurodegenerative disorder.Roth, however, reiterated a ‘Buy’ rating on the stock and a $30 price target.<h2 class="st-heading-2">How Did CLNN Retail Traders React?</h2>On Stocktwits, retail sentiment around CLNN stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.<a href="https://stocktwits.com/symbol/CLNN">CLNN stock</a> has gained over 165% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rgnx-stock-on-track-for-worst-day-ever-as-big-q1-loss-cash-concerns-eclipse-duchenne-trial-success/cZX1zjuReSX">RGNX Stock On Track For Worst Day Ever As Big Q1 Loss, Cash Concerns Eclipse Duchenne Trial Success</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

CLNN Stock Falls After Roth Labels Accelerated Approval For ALS Drug A ‘Long Shot’  

Shares of the company rose 8% during regular trading hours but fell after hours following the analyst note. 

Equity

Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates

Clene (CLNN) delivered earnings and revenue surprises of +38.00% and -62.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Beats Revenue Estimates

BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of +15.39% and +0.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Clene (NASDAQ:CLNN) Major Shareholder Sells $34,827.95 in Stock

Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 5,795 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $6.01, for a total value of $34,827.95. Following the sale, the insider directly owned 271,774 shares in the...

Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 72,884 Shares

Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 72,884 shares of Clene stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average...

Promising Nanotechnology Stocks To Watch Today - May 5th

Onto Innovation, Clene, NVE, and Nano Dimension are the seven Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of companies whose...

Nanotechnology Stocks To Watch Today - May 4th

Onto Innovation, Clene, NVE, and Nano Dimension are the five Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of companies whose core activities involve developing, manufacturing, or commercializing products and processes that man...

Clene's (CLNN) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reissued a "buy" rating and issued a $31.00 price target on shares of Clene in a research note on Monday...

<ul class="summary-bullets"><li>The agency said NfL could be used as a marker to predict patient benefit, but more data is still needed to confirm that link.</li><li>Clene plans to submit its NDA in the third quarter of 2026.</li><li>The firm’s CNM-Au8 has demonstrated a favorable safety profile with no serious treatment-related side effects.</li></ul>Shares of Clene Inc. (CLNN) climbed more than 8% on Monday after a positive update from the U.S. Food and Drug Administration signaled a potentially faster path to approval for its experimental ALS treatment.<a href="https://stocktwits.com/symbol/CLNN">CLNN shares</a> traded at their highest levels in 2026.<h2 class="st-heading-2">Clene To Submit NDA By Q3 2026</h2>According to the company, following a recent meeting, the FDA noted that its data, particularly changes in the neurofilament light (NfL) biomarker, may support a New Drug Application (NDA) under the accelerated pathway. The biomarker indicates active damage to nerve cells.The agency said NfL could be used as a marker to predict patient benefit, but more data is still needed to confirm that link. Clene plans to submit its NDA in the third quarter of 2026.“We are encouraged by the FDA’s careful evaluation of the benefits and risks associated with Clene’s ALS drug candidate, CNM-Au8, including the biomarker data the company provided. We are committed to working with the Agency on this filing and are conducting the Phase 3 confirmatory study for CNM-Au8, which we intend to commence in the first quarter of 2027,” said Rob Etherington, President and CEO of Clene.Clene’s experimental ALS drug CNM-Au8 showed strong biomarker and safety results. CNM-Au8 has also demonstrated a favorable safety profile with no serious treatment-related side effects reported.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for CLNN on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, accompanied by ‘extremely high’ message volumes.One user said the acceptance of the NDA is near certainty.<stembedurl>https://stocktwits.com/Takeover24/message/652164418</stembedurl>Another user said, despite the positive news, “retail investors have yet to grasp its true significance.”<stembedurl>https://stocktwits.com/Verudoxi/message/652161629</stembedurl>The stock has gained more than 5% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-cnsp-stock-surge-330-percent-today/cZQMtUXReJB">Why Did CNSP Stock Surge 330% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

CLNN Stock Rises 8% – Here’s What The FDA Update Means For Clene’s ALS Treatment

 The U.S. Food and Drug Administration noted that Clene’s data, particularly changes in the neurofilament light biomarker, may support a New Drug Application under an accelerated pathway.

Clene Stock Jumps After FDA Opens Door To Accelerated Approval For ALS Drug

FDA signals accelerated pathway for Clene's ALS drug CNM-Au8, with NDA filing planned and mixed technical indicators in focus.read more...

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Current Price	$6.91
Prev Close	$7.14
Open	$7.01
Dividend Yield	0.00%
50-Day Moving Average	$6.09
Beta	0.99
Avg. Volume	78,540.13
PE Ratio	-2.23

52-Week High	$13.50
52-Week Low	$2.28
Market Capitalization	$91.24M
EPS (Annual)	-$2.65
Price to Book	-4.47
Revenue Per Employee	$2,531.65

CLNN
Clene Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CLNN News

CLNNClene Inc